Nu Skin Enterprises (NUS) Restates Q1 Financials Following Audit Committee Determination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
JPMorgan Downgrades Nu Skin Enterprises (NUS) to Neutral
August 7, 2014 6:47 AM EDTJPMorgan downgraded Nu Skin Enterprises (NYSE: NUS) from Overweight to Neutral with a price target of $50.00 (from $100.00).
For an analyst ratings summary and ratings history on Nu Skin Enterprises click here. For more ratings news on Nu Skin Enterprises click here.
Shares of Nu Skin Enterprises closed at $46.52 yesterday.
... MoreNu Skin Enterprises (NUS) Slammed on Q2 'Miss', Q3 Warning
August 6, 2014 8:15 AM EDTNu Skin Enterprises (NYSE: NUS) is down a quick 15% on disappointing Q2 results and outlook. Peers are also on watch: Herbalife Ltd. (NYSE: HLF) (-1.7%) and USANA Health Sciences Inc. (NYSE: USNA).
... More
Nu Skin Enterprises Inc. (NUS) Misses Q2 EPS by 14c; Warns for Q3
August 6, 2014 7:32 AM EDTNu Skin Enterprises Inc. (NYSE: NUS) reported Q2 EPS of $1.13, $0.14 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $650 million versus the consensus estimate of $709.03 million.
Nu Skin Enterprises Inc. sees Q3 2014 EPS of $0.90-$0.95, versus the consensus of $1.68. Nu Skin Enterprises Inc. sees Q3 2014... More
